UoN partners with International Vaccine Initiative on Cholera Conjugate Vaccine Phase II Trial

The KAVI-Institute of Clinical Research (KAVI-ICR) at the University of Nairobi is advancing global vaccine science as a key partner in the upcoming Phase II clinical trial of a cholera conjugate vaccine. This trial aims to provide stronger, longer-lasting protection against cholera, particularly for children under five years, who face the highest risk.

Nairobi Investigators’ Meeting

In August 2025, Nairobi hosted the Investigators’ Meeting, a pivotal step in trial preparations, bringing together investigators, coordinators, and community engagement leads. The gathering was organized by the International Vaccine Institute (IVI) in collaboration with KAVI-ICR, Massachusetts General Hospital–Harvard University, and Croissance Clinical Research – Africa (CCR-A).

Representing the University of Nairobi, Prof. Walter Jaoko, Principal Investigator for the trial, supported by Prof Omu Anzala and Dr. Marianne Mureithi, Director of KAVI-ICR, engaged with global partners to align on study protocols, strengthen operational systems, and reinforce community engagement efforts.

Strengthening Partnerships and Impact

The collaboration underscores the value of trusted partnerships, robust research infrastructure, and community-centered science. Together, the teams are preparing to generate high-quality evidence on the cholera conjugate vaccine, which has the potential to transform cholera prevention strategies in Africa and beyond.

University of Nairobi’s Commitment

This initiative reflects the University of Nairobi’s enduring commitment to research excellence, public health impact, and building African leadership in clinical trials. Through KAVI-ICR’s strong scientific platform, the University continues to play a leading role in advancing solutions for global health challenges.